Clinical Trial Update: Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update: acalabrutinib in Indian patients with chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2024-11-22